Payment overview · 2025
General Payments
$23,981.85
109 reported records · 17 companies
Healthcare provider profile · identity verified
Angela D Watson, DO
Allopathic & Osteopathic Physicians|Internal Medicine · MEMPHIS, TN · NPI 1275601346
Verified facts
What the public records show
CMS Open Payments records show Angela D Watson, DO received $23,981.85 in general payments during 2025 across 109 reported records.
Lilly USA, LLC accounted for 95.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Nayzilam, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Tresiba by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1187 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Soliqua 100-33 by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nayzilam as an associated drug or biological on 9542 records involving 3826 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nayzilam by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22,955.84 | 95.7% | 64 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $181.59 | 0.8% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $173.46 | 0.7% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.97 | 0.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $99.38 | 0.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $73.18 | 0.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.31 | 0.3% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $61.55 | 0.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.49 | 0.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $43.20 | 0.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.59 | 0.2% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $39.40 | 0.2% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $27.78 | 0.1% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.37 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.87 | 0.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.98 | 0.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.89 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,800.00 | 18 |
| Travel and Lodging | $5,319.11 | 21 |
| Food and Beverage | $1,862.74 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $12,961.92 | 48 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $224.79 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $173.46 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $112.22 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $100.97 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $84.48 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $61.55 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.27 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.63 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.49 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $42.11 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.59 | 2 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $39.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1187 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 35 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Nayzilam nayzilam |
2025 | Nayzilam | 2024 | 17 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
85 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1187 | 137 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
169 | 54 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Nayzilam open payments reported associated product |
CMS Open Payments — General Payments 9542 supporting records · 3826 recipient NPIs · example record 1224348539 |
Nayzilam · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1905 | 391 |
| Amlodipine Besylate | Amlodipine Besylate | 1793 | 392 |
| Eliquis | Apixaban | 1187 | 137 |
| Furosemide | Furosemide | 1071 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 883 | 120 |
| Carvedilol | Carvedilol | 657 | 149 |
| Metoprolol Tartrate | Metoprolol Tartrate | 611 | 138 |
| Tamsulosin Hcl | Tamsulosin Hcl | 580 | 95 |
| Levetiracetam | Levetiracetam | 579 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 517 | 112 |
| Losartan Potassium | Losartan Potassium | 511 | 136 |
| Clopidogrel | Clopidogrel Bisulfate | 472 | 101 |
| Donepezil Hcl | Donepezil Hcl | 461 | 81 |
| Metformin Hcl | Metformin Hcl | 450 | 80 |
| Hydralazine Hcl | Hydralazine Hcl | 439 | 107 |
| Potassium Chloride | Potassium Chloride | 374 | 91 |
| Omeprazole | Omeprazole | 360 | 96 |
| Lisinopril | Lisinopril | 349 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 341 | 84 |
| Xarelto | Rivaroxaban | 338 | 29 |
| Memantine Hcl | Memantine Hcl | 334 | 58 |
| Trazodone Hcl | Trazodone Hcl | 316 | 60 |
| Alprazolam | Alprazolam | 311 | 55 |
| Divalproex Sodium | Divalproex Sodium | 297 | 47 |
| Sertraline Hcl | Sertraline Hcl | 295 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 282 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 251 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 74 |
| Mirtazapine | Mirtazapine | 242 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 239 | 51 |
| Januvia | Sitagliptin Phosphate | 235 | 30 |
| Prednisone | Prednisone | 234 | 97 |
| Risperidone | Risperidone | 234 | 37 |
| Simvastatin | Simvastatin | 228 | 49 |
| Allopurinol | Allopurinol | 224 | 55 |
| Gabapentin | Gabapentin | 209 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 41 |
| Lactulose | Lactulose | 185 | 39 |
| Famotidine | Famotidine | 178 | 41 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 169 | 54 |
| Baclofen | Baclofen | 168 | 31 |
| Latanoprost | Latanoprost | 168 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 28 |
| Midodrine Hcl | Midodrine Hcl | 161 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 29 |
| Buspirone Hcl | Buspirone Hcl | 153 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 71 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 146 | 24 |
| Olanzapine | Olanzapine | 146 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 136 | 35 |
| Montelukast Sodium | Montelukast Sodium | 133 | 30 |
| Clonidine Hcl | Clonidine Hcl | 131 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 48 |
| Spironolactone | Spironolactone | 127 | 35 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 124 | 49 |
| Azithromycin | Azithromycin | 117 | 78 |
| Meloxicam | Meloxicam | 117 | 34 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 109 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 98 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 15 |
| Glipizide | Glipizide | 96 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 95 | 12 |
| Finasteride | Finasteride | 94 | 14 |
| Linzess | Linaclotide | 92 | 18 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 91 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 91 | 25 |
| Bumetanide | Bumetanide | 90 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 32 |
| Lamotrigine | Lamotrigine | 90 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 86 | 18 |
| Brilinta | Ticagrelor | 85 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 83 | 16 |
| Ozempic | Semaglutide | 80 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 17 |
| Fluconazole | Fluconazole | 77 | 39 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 76 | suppressed |
| Colchicine | Colchicine | 75 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 75 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 12 |
| Sucralfate | Sucralfate | 74 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 72 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 17 |
| Benazepril Hcl | Benazepril Hcl | 70 | 15 |
| Glimepiride | Glimepiride | 70 | 13 |
| Humalog | Insulin Lispro | 70 | 31 |
| Memantine Hcl Er | Memantine Hcl | 69 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 18 |
| Sevelamer Carbonate | Sevelamer Carbonate | 65 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 26 |
| Ezetimibe | Ezetimibe | 64 | 17 |
| Divalproex Sodium Er | Divalproex Sodium | 63 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 62 | 17 |
| Nifedipine Er | Nifedipine | 61 | 15 |
| Methocarbamol | Methocarbamol | 60 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 14 |
| Alendronate Sodium | Alendronate Sodium | 59 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 32 |
| Ibuprofen | Ibuprofen | 58 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 14 |
| Entresto | Sacubitril/Valsartan | 56 | 15 |
| Metformin Hcl Er | Metformin Hcl | 56 | 18 |
| Bupropion Xl | Bupropion Hcl | 55 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 54 | 12 |
| Methimazole | Methimazole | 53 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 34 |
| Albuterol Sulfate | Albuterol Sulfate | 50 | 31 |
| Dapagliflozin | Dapagliflozin Propanediol | 50 | 12 |
| Jardiance | Empagliflozin | 50 | suppressed |
| Carbamazepine | Carbamazepine | 49 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 48 | 18 |
| Oxcarbazepine | Oxcarbazepine | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 20 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 45 | suppressed |
| Timolol Maleate | Timolol Maleate | 45 | 12 |
| Digoxin | Digoxin | 44 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 43 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 17 |
| Lorazepam | Lorazepam | 42 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | suppressed |
| Phenytoin | Phenytoin | 40 | suppressed |
| Scopolamine | Scopolamine | 40 | 15 |
| Lokelma | Sodium Zirconium Cyclosilicate | 39 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 15 |
| Atenolol | Atenolol | 38 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 38 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 38 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 26 |
| Amoxicillin | Amoxicillin | 36 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | 12 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 36 | suppressed |
| Lidocaine | Lidocaine | 36 | 11 |
| Farxiga | Dapagliflozin Propanediol | 35 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 25 |
| Megestrol Acetate | Megestrol Acetate | 34 | 13 |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Insulin Lispro | Insulin Lispro | 33 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | 11 |
| Aripiprazole | Aripiprazole | 32 | 11 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 31 | suppressed |
| Multaq | Dronedarone Hcl | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 18 |
| Lithium Carbonate | Lithium Carbonate | 30 | suppressed |
| Novolog | Insulin Aspart | 30 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 30 | 12 |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 29 | 12 |
| Promethazine Hcl | Promethazine Hcl | 29 | 22 |
| Clonidine | Clonidine | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 11 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 28 | suppressed |
| Levemir | Insulin Detemir | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 25 | suppressed |
| Risperidone Er | Risperidone Microspheres | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 19 |
| Felbamate | Felbamate | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Tresiba | Insulin Degludec | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Budesonide Ec | Budesonide | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Sulfasalazine | Sulfasalazine | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Minoxidil | Minoxidil | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 15 |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Nayzilam | Midazolam | 17 | 17 |
| Nystop | Nystatin | 17 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Admelog | Insulin Lispro | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glucagon Emergency Kit | Glucagon | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 14 | suppressed |
| Bicalutamide | Bicalutamide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Methazolamide | Methazolamide | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Prilosec | Omeprazole Magnesium | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
| Tirosint-Sol | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $23,981.85 · 109 records | Lilly USA, LLC | AIRSUPRA, AMVUTTRA, AREXVY, CAPLYTA, ELIQUIS, FABRAZYME, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, Nayzilam, Ozempic, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, XIFAXAN, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error